Drugs / BXP154
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05837338 | May → Jul 2023 | bleeding disorder, vascular-type | Bio 54, LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BXP154 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05837338 ↗ |
| Route | Topical | “BXP154 will be self-administered topically following wound induction” NCT05837338 ↗ |